Nucleotide and amino acid diversities of E2/NS1 hypervariable region 1 and response to interferon therapy in patients with chronic hepatitis C virus infection

Hepatology Research

Volumn 11, Issue 3, 1998, Pages 166-177

  Cao, Kun ^a   Mizokami, Masashi ^a   Orito, Etsuro ^a   Ohno, Tomoyoshi ^a   Nakano, Tatsunori ^a   Ding, Xin ^a   Ohba, Ken Ichi ^b   Mizuno, Yoshiki ^b   Hayashi, Katsuo ^b   Kumada, Kazunori ^b  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Nagoya City Higashi General Hospital   (Japan)

Author keywords

HCV genotype 1b; HVR1; IFN; Nucleotide and amino acid diversities; Viremia

Indexed keywords

INTERFERON;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DNA FLANKING REGION; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; VIRUS GENOME;

EID: 0031826219     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(98)00028-x     Document Type: Article

References (26)

1. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-361.
2. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., Furuta S., Akahane Y., Nishioka K., Purcell R.H., Alter H.J. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:1990;671-675.
3. The Hepatitis International Therapy Group, Davis G.L., Balart L.A., Schiff E.R., Lindsay K., Bodenheimer H.C., Perrillo R.P., Carey W., Jacobson I.M., Payne J., Dienstag J.L., Van Thiel D.H., Tamburro C., Lefkowitch J., Albrecht J., Meschievitz C., Ortego T.J., Gibas A. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med. 321:1989;1501-1506.
4. Marcellin P., Boyer N., Giostra E., Degott C., Courouce M.A., Degos F., Coppere H., Cales P., Couzigou P., Benhanmou J.P. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
5. Yoshioka K., Kakumu S., Wakita T., Ishikawa T., Itoh Y., Takayanagi M., Higashi Y., Shibata M., Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology. 16:1992;293-299.
6. Lau J.Y.N., Davis G.L., Knniffen J., Qian K.-P., Urdea M.S., Chan C.S., Mizokami M., Neuwald P.D., Wilber J.C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
7. Tsubota A., Chayama K., Ikeda K., Yasoji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsu K. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology. 19:1994;1088-1094.
8. Orito E., Mizokami M., Mizoguchi N., Ohba K., Tohnai M., Yamanaka H., Oguri T., Hirashima N., Koide T., Kano H., Tsukiyama-Kohara K., Kohara M., Lau J.Y.N. Hepatitis C virus serotype II responds more favorably to interferon-α therapy. J Hepatol. 21:1994;130-132.
9. Okada S., Akahane Y., Suzuki H., Okamoto H., Mishiro S. The degree of variability in the amino terminal region of the E2/NS 1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology. 16:1992;619-624.
10. Kanazawa Y., Hayashi N., Mita E., Li T., Hagiwara H., Kasahara A., Fusamoto H., Kamada T. Influence of viral quasispecies on effectiveness of interferon therapy in chronic C patients. Hepatology. 20:1994;1121-1130.
11. Gonzalez-Peralta R.P., Qian K.P., She J.Y., Davis G.L., Ohno T., Mizokami M., Lau J.Y.N. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C virus infection. J Med Virol. 49:1996;242-247.
12. Ichida F., Tsuji T., Omata M., Ichida T., Inoue K., Kamimura T., Yamada G., Hino K., Yokosuka O., Suzuki H. New inuyama classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 6:1996;112-119.
13. Davis G.L., Lau J.Y.N., Urdea M.S., Neuwald P., Wilber J.C., Lindsay K., Perrillo R.P., Albrecht J. Quantitative detection of hepatitis C virus (HCV) RNA by a solid phase branched chain DNA amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology. 19:1994;1337-1341.
14. Lau J.Y.N., Davis G.L., Orito E., Qian K.-P., Mizokami M. Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection. J Hepatol. 17:1993;253-257.
15. Okamoto H., Okada S., Sugiyama Y., Tanaka T., Sugai Y., Akahane Y., Machida A., Mishiro S., Yoshizawa H., Miyakawa Y., Mayumi M. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′ non-coding region. Jpn J Exp Med. 60:1990;215-222.
16. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y., Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 73:1992;673-679.
17. Simmonds P., Alberti A., Alter H.J.et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 19:1994;1321-1324.
18. Gojobori T., Ishii K., Nei M. Estimation of average number of nucleotide substitutions when the rate of substitution varies with nucleotide. J Mol Evol. 18:1982;414-423.
19. Koizumi K., Enomoto N., Kurosaki M., Murakami T., Izumi N Marumo F., Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology. 22:1995;30-35.
20. Moribe T., Hayashi N., Kanazawa Y., Mita E., Fusamoto H., Negi M., Kaneshige T., Igimi H., Kamada T., Uchida K. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology. 108:1995;789-795.
21. Nagasaka A., lIige S., Tsunematsu I., Yoshida J., Sasaki Y., Matsushima T., Asaka M. Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy. J Med Virol. 50:1996;214-220.
22. Mizokami M., Gojobori T., Lau J.Y.N. Molecular evolutionary virology: its application to hepatitis C virus. Gastroenterology. 107:1994;1181-1182.
23. Nakazawa T., Kato N., Ohkoshi S., Shibuya A., Shimotohno K. Characterization of the 5′ non-coding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. J Hepatol. 20:1994;623-629.
24. Shindo M., Hamada K., Koya S., Arai K., Sokawa Y., Okuno T. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology. 24:1996;1018-1023.
25. Toyoda H., Kumada T., Nakano S., Takeda I., Sugiyama K., Osada T., Kiriyama S., Sone Y., Kinoshita M., Hadama T. Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol. 26:1997;6-13.
26. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., Sato C. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:1996;77-81.